Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brooke E Howitt

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Nature Biomedical Engineering|June 19, 2024
A pathologist-AI collaboration framework for enhancing diagnostic accuracies and efficienciesZhi Huang, Eric Yang, Jeanne Shen, et al.
Gynecologic Oncology|April 25, 2025
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeuticsKari L Ring, Anne M Mills, Brooke E Howitt, et al.
The American Journal of Surgical Pathology|March 21, 2024
The Malignant Potential of Ovarian Steroid Cell Tumors Revisited: A Multi-institutional Clinicopathologic Analysis of 115 CasesOluwole Fadare, Elmira Vaziri Fard, Rohit Bhargava, et al.
The Journal of Pathology|July 31, 2024
Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinomaRodrigo Vallejos, Almira Zhantuyakova, Gian Luca Negri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial CarcinomasAmy Jamieson, Lisa Vermij, Claire J H Kramer, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencingSydney B Blattman, Nabih Maslah, Austin A Varela, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Nature|November 7, 2024
Origins and impact of extrachromosomal DNAChris Bailey, Oriol Pich, Kerstin Thol, et al.
Cell Reports. Medicine|January 20, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomasShiqin Liu, Timothy Chai, Fernando Garcia-Marques, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Nature Biomedical Engineering|June 19, 2024
A pathologist-AI collaboration framework for enhancing diagnostic accuracies and efficienciesZhi Huang, Eric Yang, Jeanne Shen, et al.
Gynecologic Oncology|April 25, 2025
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeuticsKari L Ring, Anne M Mills, Brooke E Howitt, et al.
The American Journal of Surgical Pathology|March 21, 2024
The Malignant Potential of Ovarian Steroid Cell Tumors Revisited: A Multi-institutional Clinicopathologic Analysis of 115 CasesOluwole Fadare, Elmira Vaziri Fard, Rohit Bhargava, et al.
The Journal of Pathology|July 31, 2024
Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinomaRodrigo Vallejos, Almira Zhantuyakova, Gian Luca Negri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial CarcinomasAmy Jamieson, Lisa Vermij, Claire J H Kramer, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencingSydney B Blattman, Nabih Maslah, Austin A Varela, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Nature|November 7, 2024
Origins and impact of extrachromosomal DNAChris Bailey, Oriol Pich, Kerstin Thol, et al.
Cell Reports. Medicine|January 20, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomasShiqin Liu, Timothy Chai, Fernando Garcia-Marques, et al.
Pageof 17